Immunotherapy—particularly immune checkpoint inhibition—has fundamentally shifted oncology. By blocking the molecular brakes that cancer cells use to evade detection, these therapies unleash the body’s cytotoxic T cells to destroy tumors. Yet, this elegant mechanism suffers from a major prerequisite: the immune system must already recognize the tumor, and T cells must already be present within the tumor microenvironment.
For the vast majority of patients, this is not the case. Most advanced malignancies are immunologically "cold"—devoid of T-cell infiltration and heavily shielded by immunosuppressive cells. As Yongjiu Dai et al. note in Perspectives on Immunotherapy of Metastatic Colorectal Cancer, this lack of immune visibility renders standard checkpoint inhibitors ineffective.
To solve this problem, a rapidly growing body of research explores an intuitive strategy: using localized radiotherapy not merely to destroy tumor tissue physically, but to act as an immune primer that turns "cold" tumors "hot."
The In-Situ Vaccine Mechanism
The core reason radiotherapy can prime a systemic immune response lies in how the radiation kills cancer cells. Normal cellular turnover typically occurs via apoptosis—a quiet, programmed cellular suicide that avoids triggering inflammation. Radiotherapy, however, can force cancer cells to undergo a highly disruptive process known as immunogenic cell death (ICD).
When a tumor is targeted with precision radiation, the dying cells do not disappear silently. Instead, they rupture and spill their contents into the surrounding tissue. As explained by Shiyu Liu et al. in Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields, this cellular collapse releases a wave of tumor-associated antigens (TAAs) alongside pro-inflammatory danger signals.
This event effectively transforms the patient's local tumor into an in-situ vaccine. Xiaoqin Ji et al. describe this phenomenon in Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors, illustrating how the sudden abundance of localized antigens trains immune-sensing cells to recognize the specific signature of the malignancy. By turning the primary tumor site into a rich source of antigens, radiation primes the immune system to recognize cells it previously ignored—a mechanism corroborated by Qian Zhang et al. in Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China.
Flipping the Microenvironmental Switch
Exposing antigens is only half the battle; the immune cells must also be able to penetrate the tumor. Cold tumors actively maintain an immunosuppressive shield, often dominated by regulatory macrophages that exclude killer T cells. Localized radiation acts as a catalyst to dismantle this defense.
Using high-resolution spatial profiling to study bone-metastatic prostate cancer, Paul G. Corn et al. demonstrated that targeted alpha-particle radiation significantly reduces these immunosuppressive macrophage populations while simultaneously promoting a robust influx of cytotoxic T cells (Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment).
This cellular influx alters the fundamental nature of the tumor microenvironment. In Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma, Ke Xu et al. showed that stereotactic body radiation therapy (SBRT) drives effector T cells directly into the heart of the tumor. By converting the microenvironment from an immune desert to an active, inflamed zone, radiation sets the stage for immunotherapy to succeed.
From Local Priming to Systemic Synergy
Once radiotherapy has acted as the match to ignite the immune response, systemic immunotherapy can be introduced to sustain it. Checkpoint inhibitors (such as anti-PD-1 antibodies) fail when T cells are absent or unprimed. By pairing radiation's ability to recruit and educate T cells with immunotherapy's ability to keep them active, the combination achieves a powerful synergy.
A systematic review by Tiankai Xu et al. confirmed that adding localized radiation to checkpoint inhibition regimens significantly improves clinical outcomes in metastatic non-small cell lung cancer by consistently converting non-responsive tumors into active targets (Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis).
[Localized Radiotherapy]
│
▼
[Immunogenic Cell Death (ICD)] ──► Releases Antigens & Danger Signals (In-Situ Vaccine)
│
▼
[Microenvironment Remodeling] ──► Recruits Cytotoxic T Cells & Reduces Suppressive Macrophages
│
▼
[Systemic Checkpoint Inhibition] ──► Unleashes Primed T Cells to Attack Distant Metastases (Abscopal Effect)
Crucially, because the immune system circulates globally, this local priming event can trigger the regression of distant, un-irradiated metastatic lesions—a phenomenon known as the abscopal effect. As Zhuo Song et al. explain in Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma, the physical destruction of a single accessible tumor site generates a systemic wave of activated T cells. These newly trained cells travel through the bloodstream, identifying and destroying metastatic deposits far beyond the original radiation beam.
This therapeutic framework is currently being adapted across a variety of challenging malignancies. For instance, Shi Fang et al. detailed a clinical protocol combining SBRT with a bispecific antibody to breach the notoriously dense, cold microenvironment of pancreatic cancer (Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer). Furthermore, clinical evidence compiled by Yanshuang Cheng et al. in head and neck cancers (Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy) and Chengxin Liu et al. in esophageal carcinoma (Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study) underscores that disrupting a tumor's genomic and cellular defenses with radiation transforms local treatment into a systemic, immune-sensitizing event.
Key Foundational Work
Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields (2020) — contributed 2 concept elements to this direction.
Perspectives on Immunotherapy of Metastatic Colorectal Cancer (2021) — contributed 2 concept elements to this direction.